Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|January 27, 2017||6/3/2018||A Phase IIa Study With Escalating Dose of MS1819-SD||A Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal Pancreatectomy||Chronic Pancreatitis;Distal Pancreatectomy||Drug: MS1819-SD||AzurRx SAS||NULL||Completed||18 Years||N/A||All||11||Phase 2||Australia;France;New Zealand|
|11/05/2010||19/03/2010||Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis||Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis||Exocrine pancreatic insufficiency resulting from chronic pancreatitis |
MedDRA version: 12.1;Level: LLT;Classification code 10033628;Term: Pancreatic insufficiency
|Product Name: MS1819|
Product Code: MS1819
INN or Proposed INN: Yarrowia lipolytica lipase
|Laboratoires Mayoly Spindler||NULL||Authorised-recruitment may be ongoing or finished||Female: yes|